These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1322155)

  • 1. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
    Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
    Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
    Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni GJ
    Eur J Cancer; 1993; 29A(2):185-9. PubMed ID: 8422280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
    Lissoni P; Meregalli S; Fossati V; Paolorossi F; Barni S; Tancini G; Frigerio F
    Tumori; 1994 Dec; 80(6):464-7. PubMed ID: 7900237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
    Aldeghi R; Lissoni P; Barni S; Ardizzoia A; Tancini G; Piperno A; Pozzi M; Ricci G; Conti A; Maestroni GJ
    Eur J Cancer; 1994; 30A(2):167-70. PubMed ID: 8155391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
    Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Paolorossi F; Brivio F; Perego M; Tancini G; Conti A; Maestroni G
    Tumori; 1992 Dec; 78(6):383-7. PubMed ID: 1297233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
    Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
    Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
    J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
    Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
    Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
    Eur J Cancer; 1993; 29A(8):1127-32. PubMed ID: 8390845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
    Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
    Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
    Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P; Mandalà M; Brivio F
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
    Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
    Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
    Lissoni P; Brivio F; Ardizzoia A; Tancini G; Barni S
    Tumori; 1993 Dec; 79(6):401-4. PubMed ID: 8171739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.